Literature DB >> 34043053

Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY).

Marion Hourqueig1, Guillaume Bouzille1, Albert Hagège2, Erwan Donal3, Mariana Mirabel4, Olivier Huttin2, Thibaud Damy5, Fabien Labombarda6, Jean-Christophe Eicher7, Philippe Charron8,9, Gilbert Habib10, Patricia Réant11.   

Abstract

AIMS: Defining the risk of atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) patients is an important clinical and prognostic challenge. The aim of this study is to determine HCM phenogroups with different risk of AF occurrence at 5 years. METHODS AND
RESULTS: We applied retrospectively the Bayesian method, which can analyze a large number of variables, to differentiate phenogroups of patients with different risks of AF and prognoses across a French prospective on-going hospital-based registry of adult HCM patients (REMY). Clinical and imaging data were prospectively recorded, and patients were followed for 5 years. A total of 1431 HCM patients were recruited, including 1275 analyzed in the present study after exclusion criteria. The population included 412 women, 369 patients with obstructive HCM, and 252 implanted with an ICD. AF occurred in 167 (11.6%) patients during the 5 year follow-up. Three phenogroups were defined according to their common clinical and echocardiographic characteristics. Patients at the highest risk were oldest, more often female, with more frequent comorbidities, anteroposterior diameter of the left atrium was significantly greater, with diastolic dysfunction, outflow-tract obstruction, and mitral valve abnormality, and presented higher pulmonary artery pressure and/or right-ventricular dysfunction. These also had a higher risk of all-cause hospitalizations and death.
CONCLUSION: Based on a clustering analysis, three phenogroups of HCM according to the risk of AF occurrence can be identified. It can indicate which patients should be more monitored and/or treated, particular to prevent the risk of stroke.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Atrial fibrillation; Clustering; Hypertrophic cardiomyopathy; Prognosis

Mesh:

Year:  2021        PMID: 34043053     DOI: 10.1007/s00392-020-01797-5

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  35 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.

Authors:  Barry J Maron; Susan A Casey; Iacopo Olivotto; Mark V Sherrid; Christopher Semsarian; Camillo Autore; Aisha Ahmed; Giuseppe Boriani; Pietro Francia; Stephen L Winters; Michael Giudici; Anna Koulova; Ross Garberich; Ethan J Rowin; Samuel F Sears; Martin S Maron; Paolo Spirito
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-04

3.  Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality.

Authors:  Thomas Zegkos; Georgios K Efthimiadis; Despoina G Parcharidou; Thomas D Gossios; Georgios Giannakoulas; Dimitris Ntelios; Antonis Ziakas; Stelios Paraskevaidis; Haralambos I Karvounis
Journal:  Hellenic J Cardiol       Date:  2017-02-20

Review 4.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.

Authors:  Oliver P Guttmann; M Shafiqur Rahman; Constantinos O'Mahony; Aris Anastasakis; Perry M Elliott
Journal:  Heart       Date:  2013-09-07       Impact factor: 5.994

5.  Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study.

Authors:  Toru Kubo; Hiroaki Kitaoka; Makoto Okawa; Takayoshi Hirota; Kayo Hayato; Naohito Yamasaki; Yoshihisa Matsumura; Toshikazu Yabe; Jun Takata; Yoshinori L Doi
Journal:  Circ J       Date:  2009-07-09       Impact factor: 2.993

6.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.

Authors:  F Cecchi; I Olivotto; A Montereggi; G Santoro; A Dolara; B J Maron
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

7.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.

Authors:  K Robinson; M P Frenneaux; B Stockins; G Karatasakis; J D Poloniecki; W J McKenna
Journal:  J Am Coll Cardiol       Date:  1990-05       Impact factor: 24.094

8.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Iacopo Olivotto; Pietro Bellone; Maria Rosa Conte; Franco Cecchi; Björn P Flygenring; Susan A Casey; Thomas E Gohman; Sergio Bongioanni; Paolo Spirito
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

9.  Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).

Authors:  Oliver P Guttmann; Menelaos Pavlou; Constantinos O'Mahony; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; Pablo Garcia-Pavia; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2015-07-16       Impact factor: 15.534

10.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).

Authors:  Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Allison L Cirino; Jonathan C Fox; Neal K Lakdawala; James S Ware; Colleen A Caleshu; Adam S Helms; Steven D Colan; Francesca Girolami; Franco Cecchi; Christine E Seidman; Gautam Sajeev; James Signorovitch; Eric M Green; Iacopo Olivotto
Journal:  Circulation       Date:  2018-08-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.